These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33987411)

  • 1. Integrated genomic and transcriptomic analysis suggests
    Li Z; Jin Y; Zou Q; Shi X; Wu Q; Lin Z; He Q; Huang G; Qi S
    Ann Transl Med; 2021 Apr; 9(8):713. PubMed ID: 33987411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative Genomic and Transcriptomic Analysis of Primary Malignant Gliomas Revealed Different Patterns Between Grades and Somatic Mutations Related to Glioblastoma Prognosis.
    Jin H; Yu Z; Tian T; Shen G; Chen W; Fan M; He Q; Dai D; Zhang X; Liu D
    Front Mol Biosci; 2022; 9():873042. PubMed ID: 35865002
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic Value of Immunohistochemical Expression of MTAP and AKIP1 in IDH1 Mutant Astrocytoma.
    Ahmed MM; Lateef MA; Elwan A; Fouad EM; Elsayed DH; Abdelnour HM; Abdullatif A
    Asian Pac J Cancer Prev; 2023 Nov; 24(11):3875-3882. PubMed ID: 38019246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral Decomposition.
    Aiello KA; Alter O
    PLoS One; 2016; 11(10):e0164546. PubMed ID: 27798635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The involvement of brain regions associated with lower KPS and shorter survival time predicts a poor prognosis in glioma.
    Bao H; Wang H; Sun Q; Wang Y; Liu H; Liang P; Lv Z
    Front Neurol; 2023; 14():1264322. PubMed ID: 38111796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
    Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
    Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities.
    Reinhardt A; Stichel D; Schrimpf D; Koelsche C; Wefers AK; Ebrahimi A; Sievers P; Huang K; Casalini MB; Fernández-Klett F; Suwala A; Weller M; Gramatzki D; Felsberg J; Reifenberger G; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Buslei R; Deckert M; Mawrin C; Hewer E; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Korshunov A; Reuss DE; Sahm F; Jones DTW; Capper D; von Deimling A
    Acta Neuropathol Commun; 2019 Oct; 7(1):163. PubMed ID: 31661039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts.
    Prosniak M; Harshyne LA; Gorky J; Curtis MT; Kenyon LC; Schwaber JS; Lebrun A; Kean RB; Andrews DW; Hooper DC
    J Immunol; 2021 Apr; 206(7):1483-1492. PubMed ID: 33685995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
    J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping.
    Lyon JF; Vasudevaraja V; Mirchia K; Walker JM; Corona RJ; Chin LS; Tran I; Snuderl M; Richardson TE; Viapiano MS
    Acta Neuropathol Commun; 2021 Jun; 9(1):120. PubMed ID: 34193272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.
    Tehrani M; Friedman TM; Olson JJ; Brat DJ
    Brain Pathol; 2008 Apr; 18(2):164-71. PubMed ID: 18093251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome analysis reveals distinct gene expression profiles in astrocytoma grades II-IV.
    Narsia N; Ramagiri P; Ehrmann J; Kolar Z
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):261-271. PubMed ID: 28452381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.